A new market study, titled “Alzheimer’s disease – Competitive Landscape and Market, Market Access Potential, Pricing, Pipeline Analysis 2019” has been featured on WiseGuyReports.
Alzheimer’s disease is the most common cause of dementia and increases in prevalence exponentially with age, with trends in the United States likely to worsen in ensuing decades.
The economic burden of Alzheimer’s disease is quite high including direct and indirect costs. Indirect costs are the most important costs in early and community-dwelling AD patients. Direct costs increase when the disorder progresses, and the patient is institutionalized or a formal caregiver is required.
Request free Sample Report at https://www.wiseguyreports.com/sample-request/3640366-alzheimer-s-disease-competitive-landscape-and-market-market
In AD, the prevalence rate doubles every 5 years and various epidemiological studies have shown the exponential growth of prevalence rate with age, starting from around 1.5-2.5% in the 65-69-year bracket, reaching almost 40% in the 90-94 year age group.1,2 In addition, according to the World Health Organization (WHO) the proportion of people over 65 years is set to increase from 6.8% in 2000 to 16.2% by 2050. As a consequence, the prevalence of dementia in 2005 (24 million) is expected to rise to 81 million by 2040, assuming no changes in incidence, mortality and current preventive or curative treatments for these disorders.
Scope of the report:
The report “Alzheimer’s disease – Competitive Landscape and Market, Market Access Potential, Pricing, Pipeline Analysis 2019” contains:
- Report has covered the current treatment landscape, detailed description of the drugs, pricing and market access aspects
- The current report contains detailed description, mechanism of action, technology, collaborations of the pipeline products. The report contains detailed description based on different phases, types and method of administration
- The report contains pipeline products that are in the various stages of the development including Phase 3, Phase 2, Phase 1, preclinical and discovery stage
- The report contains dormant and discontinued products
Why to buy:
The report provides a comprehensive overview of the current treatment landscape, unmet needs and expectations from the future therapies.
The report helps our clients in making key business decisions with respect to investment
With a comprehensive report contains the different products and companies involved, it helps in identifying the commercial opportunities
Table of Content
Current Treatment landscape
Currently approved products
- Memantine Merz
- Rivastigmine 1 A Pharma
- Rivastigmine Hexal
- Rivastigmine SandozFrance : HTA analysis
Germany: HTA analysis
United Kingdom: HTA analysis
Italy: HTA analysis
United States: HTA analysis
An Overview of Pipeline
Therapeutics under Development by companies
Late stage products
Mid stage products
Early stage products
Assessment by Phase
Wise Guy Reports is part of the Wise Guy Research Consultants Pvt. Ltd. and offers premium progressive statistical surveying, market research reports, analysis & forecast data for industries and governments around the globe.
Ph: +1-646-845-9349 (US)
Ph: +44 208 133 9349 (UK)